Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Comprehensive Overview of Globally Approved JAK Inhibitors
Ahmed M. Shawky, Faisal A. Almalki, Ashraf N. Abdalla, et al.
Pharmaceutics (2022) Vol. 14, Iss. 5, pp. 1001-1001
Open Access | Times Cited: 198

Showing 1-25 of 198 citing articles:

Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update
Robert Roskoski
Pharmacological Research (2022) Vol. 187, pp. 106552-106552
Open Access | Times Cited: 239
Macrocycles in Drug Discovery─Learning from the Past for the Future
Diego García Jiménez, Vasanthanathan Poongavanam, Jan Kihlberg
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 8, pp. 5377-5396
Open Access | Times Cited: 129
JAK-STAT signaling in inflammation and stress-related diseases: implications for therapeutic interventions
Alexey Sarapultsev, Evgeni Gusev, Maria Komelkova, et al.
Molecular Biomedicine (2023) Vol. 4, Iss. 1
Open Access | Times Cited: 55
Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis
Robert Roskoski
Pharmacological Research (2023) Vol. 189, pp. 106642-106642
Open Access | Times Cited: 45
JAK-STAT pathway inhibitors in dermatology
Hélio Amante Miot, Paulo Ricardo Criado, Caio César Silva de Castro, et al.
Anais Brasileiros de Dermatologia (2023) Vol. 98, Iss. 5, pp. 656-677
Open Access | Times Cited: 44
Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders
Robert Roskoski
Pharmacological Research (2022) Vol. 183, pp. 106362-106362
Closed Access | Times Cited: 61
Tyk2 Targeting in Immune-Mediated Inflammatory Diseases
Lluís Rusiñol, L. Puig
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 3391-3391
Open Access | Times Cited: 39
The ins and outs of innate and adaptive type 2 immunity
Ari B. Molofsky, Richard M. Locksley
Immunity (2023) Vol. 56, Iss. 4, pp. 704-722
Open Access | Times Cited: 35
Multidimensional definition of the interferonopathy of Down syndrome and its response to JAK inhibition
Matthew D. Galbraith, Angela L. Rachubinski, Keith P. Smith, et al.
Science Advances (2023) Vol. 9, Iss. 26
Open Access | Times Cited: 35
The Importance of the Pyrazole Scaffold in the Design of Protein Kinases Inhibitors as Targeted Anticancer Therapies
George Mihai Niţulescu, Gheorghe Stancov, Oana Cristina Șeremet, et al.
Molecules (2023) Vol. 28, Iss. 14, pp. 5359-5359
Open Access | Times Cited: 33
Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases
Peter C. Taylor, Ernest Choy, Xenofon Baraliakos, et al.
Lara D. Veeken (2023) Vol. 63, Iss. 2, pp. 298-308
Open Access | Times Cited: 32
New and Emerging Oral/Topical Small-Molecule Treatments for Psoriasis
Elena Carmona‐Rocha, Lluís Rusiñol, L. Puig
Pharmaceutics (2024) Vol. 16, Iss. 2, pp. 239-239
Open Access | Times Cited: 14
Comparative efficacy of oral Janus kinase inhibitors and biologics in adult alopecia areata: A systematic review and Bayesian network meta‐analysis
Husein Husein‐ElAhmed, Sara Husein‐ElAhmed
Journal of the European Academy of Dermatology and Venereology (2024) Vol. 38, Iss. 5, pp. 835-843
Closed Access | Times Cited: 13
The JAK-STAT pathway: from structural biology to cytokine engineering
You Lv, Jianxun Qi, Jeffrey J. Babon, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 13
Small molecule drug discovery targeting the JAK-STAT pathway
You Lv, Pengbing Mi, Jeffrey J. Babon, et al.
Pharmacological Research (2024) Vol. 204, pp. 107217-107217
Open Access | Times Cited: 12
SOCS1 is a critical checkpoint in immune homeostasis, inflammation and tumor immunity
Grace M. Bidgood, Narelle Keating, Karen Doggett, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 12
Targeted Treatment against Cancer Stem Cells in Colorectal Cancer
Julia Martínez-Pérez, C. Sevillano, Maria A Dominguez-Cejudo, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 6220-6220
Open Access | Times Cited: 10
Review article: Novel therapies in inflammatory bowel disease – An update for clinicians
Nurulamin M Noor, Alice Bourke, Sreedhar Subramanian
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 9, pp. 1244-1260
Open Access | Times Cited: 10
JAK Inhibitors in Cutaneous T-Cell Lymphoma: Friend or Foe? A Systematic Review of the Published Literature
Seyed Mohammad Vahabi, Saeed Bahramian, Farzad Esmaeili, et al.
Cancers (2024) Vol. 16, Iss. 5, pp. 861-861
Open Access | Times Cited: 9
Synthetic Approaches to the New Drugs Approved During 2022
Scott P. France, Erick A. Lindsey, Emma L. McInturff, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 6, pp. 4376-4418
Closed Access | Times Cited: 9
Therapeutic potential of anticancer activity of nitrogen-containing heterocyclic scaffolds as Janus kinase (JAK) inhibitor: Biological activity, selectivity, and structure–activity relationship
Rohit Pal, Gurubasavaraja Swamy Purawarga Matada, Ghanshyam Teli, et al.
Bioorganic Chemistry (2024) Vol. 152, pp. 107696-107696
Closed Access | Times Cited: 9
Janus kinase inhibitors and the changing landscape of vitiligo management: a scoping review
Amelia Utama, Ruki Wijesinghe, Steven Tien Guan Thng
International Journal of Dermatology (2024) Vol. 63, Iss. 8, pp. 1020-1035
Open Access | Times Cited: 8
Evaluation of Real-World Evidence to Assess Effectiveness Outcomes of Janus Kinase Inhibitors for Rheumatoid Arthritis: A Systematic Review of US Studies
Chandler Gandy, Shadi Bazzazzadehgan, Sebastian Bruera, et al.
Drug Healthcare and Patient Safety (2025) Vol. Volume 17, pp. 25-49
Open Access | Times Cited: 1
Matrix mechano-sensing at the invasive front induces a cytoskeletal and transcriptional memory supporting metastasis
Óscar Maiques, Marta C. Sallán, Roman Laddach, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis
Helena Iznardo, Esther Roé, E. Serra‐Baldrich, et al.
Pharmaceutics (2023) Vol. 15, Iss. 2, pp. 385-385
Open Access | Times Cited: 21
Page 1 - Next Page

Scroll to top